Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 27, 2025 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the appointment of Dr. Pejvack Motlagh, the new Chief Medical Officer of GENFIT. Member of the Executive Committee, Dr. Motlagh will oversee the strategy, direction, and execution of GENFIT’s clinical development plans and lead the Clinical (Operation ...

One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally.New York City-based Findell Capital Management disclosed a new $9.5 million position in Mineralys Therapeutics (MLYS +2.75%) as of its November 14 SEC filing.What HappenedAccording to a filing with the Securities and Exchange Commission dated November 14, Findell Capital Management initiated a new position in Mineralys Therapeutics (MLYS +2.75%), acquiring 250,000 shares in the third quarter. The s ...

In this piece, we will discuss the 12 hot penny stocks to invest in right now.Amid an uncertain macro environment, where the economic outlook is blurry, the momentum of penny stocks depends heavily on shifting market psychology rather than macro certainty.Goldman Sachs Asset Management portfolio manager Greg Tuorto appeared on CNBC on November 17, 2025. Despite the uncertainty around the timing of rate cuts, he noted that small-cap stocks are quietly building their own momentum. The small-cap segment is att ...

In my opinion, Incyte Corporation ( INCY ) is one of the most interesting businesses in biopharmaceuticals for fans of value investing. High revenue growth rates, high business margins compared to sectoral competitors, and aHi there! I’m Narek, and I’ve been in the investment world for over six years. I started out as an equity analyst at European banks, digging into reports and learning how to spot value in the markets. I’ve worked across sectors — from telecom to industry — and found that behind every fin ...

Core Insights - Incyte Corporation (INCY) is highlighted as a compelling investment opportunity within the biopharmaceutical sector, particularly for value investors due to its high revenue growth rates and superior business margins compared to competitors [1]. Group 1: Company Performance - Incyte exhibits high revenue growth rates, making it an attractive option for investors [1]. - The company maintains high business margins relative to its sectoral competitors, indicating strong operational efficiency [1].

Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a biopharmaceutical company focused on developing and commercializing innovative medicines. The company's primary focus is on sleep disorders, with its lead product being a treatment for narcolepsy. Avadel operates in a competitive landscape alongside other biopharmaceutical companies like Eyenovia, Aquestive Therapeutics, Clearside Biomedical, and Intra-Cellular Therapies.In evaluating Avadel's financial performance, the Return on Invested Capital (ROIC) is a key ...

Core Insights - HUTCHMED will present new and updated data from several studies at the upcoming ESMO Asia Congress 2025 and ASH Annual Meeting, showcasing its commitment to advancing cancer therapies [1][2][3] Group 1: Upcoming Presentations - A first-in-human study of HMPL-A83, an anti-CD47 monoclonal antibody, will be presented, focusing on advanced solid tumors [2] - The phase II results of the FRUSICA-2 study, evaluating the combination of fruquintinib and sintilimab for renal cell carcinoma, will also be shared [2] - Surufatinib's phase II results in combination with camrelizumab and chemotherapy for metastatic pancreatic cancer will be reported [2] Group 2: Specific Study Details - HMPL-A83 presentation details include a mini oral session on December 7, 2025, led by Ye Guo [2] - Fruquintinib's results will be presented by Shanshan Wang on December 5, 2025, in a proffered paper session [2] - Surufatinib's study will be displayed as a poster by Shukui Qin [2] Group 3: Additional Studies - Several investigator-initiated studies will also be presented, including combinations of fruquintinib with other treatments for metastatic colorectal cancer [3] - The final analysis of the ESLIM-01 study on sovleplenib for chronic primary immune thrombocytopenia will be presented at the ASH Annual Meeting [3] Group 4: Product Information - Fruquintinib is a selective oral inhibitor of VEGFRs, co-developed by HUTCHMED and Eli Lilly, marketed as ELUNATE in China [4] - HMPL-A83 is a humanized anti-CD47 monoclonal antibody that disrupts cancer cells' immune evasion [5] - Savolitinib is a selective MET tyrosine kinase inhibitor developed by AstraZeneca and HUTCHMED, marketed as ORPATHYS [6] - Surufatinib is an oral angio-immuno kinase inhibitor marketed as SULANDA in China [7] - Sovleplenib is a selective small molecule inhibitor targeting Syk, with potential applications in B-cell lymphomas [8]

Launched search for permanent successorGARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Doug Larson has resigned as Chief Financial Officer to pursue another opportunity. Mr. Larson will continue to serve as CFO through December 5, 2025, at which time the CFO responsibil ...

BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R. Meyers, an accomplished biopharmaceutical executive with over three decades of commercial leadership experience to Vera Therapeutics’ Board of Directors. "We are thrilled to welcome Jim to our Board of Directors at ...

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats at two upcoming investor conferences: 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 9:35 a.m. ET in Miami, FL. ...